Go Pro
→ Iran's New Leader Just Said Something That Should Terrify Every American (From American Alternative) (Ad)tc pixel Free BPCR Stock Alerts

BioPharma Credit (BPCR) Competitors

BioPharma Credit logo
GBX 0.96 0.00 (0.00%)
As of 12:37 PM Eastern
Compare

BPCR vs. LGT, RIV, BRIG, SGEM, and NBMI

Should you buy BioPharma Credit stock or one of its competitors? MarketBeat compares BioPharma Credit with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioPharma Credit include Lighthouse Group (LGT), River and Mercantile Group (RIV), BlackRock Income and Growth (BRIG), ScotGems (SGEM), and NB Global Monthly Income Fund Ltd GBP (NBMI). These companies are all part of the "asset management" industry.

How does BioPharma Credit compare to Lighthouse Group?

Lighthouse Group (LON:LGT) and BioPharma Credit (LON:BPCR) are both small-cap asset management industry companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

Lighthouse Group pays an annual dividend of GBX 0.01 per share. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 729.2%. Lighthouse Group pays out 0.6% of its earnings in the form of a dividend. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, Lighthouse Group's average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score.

Company Overall Sentiment
Lighthouse Group Neutral
BioPharma Credit Neutral

31.3% of BioPharma Credit shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BioPharma Credit has higher revenue and earnings than Lighthouse Group. Lighthouse Group is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lighthouse Group£53.42M0.00N/A£1.80N/A
BioPharma Credit£132.06M0.08£10.42B£11.400.08

BioPharma Credit has a net margin of 92.62% compared to Lighthouse Group's net margin of 0.00%. BioPharma Credit's return on equity of 11.29% beat Lighthouse Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Lighthouse GroupN/A N/A N/A
BioPharma Credit 92.62%11.29%4.98%

Summary

BioPharma Credit beats Lighthouse Group on 8 of the 10 factors compared between the two stocks.

How does BioPharma Credit compare to River and Mercantile Group?

BioPharma Credit (LON:BPCR) and River and Mercantile Group (LON:RIV) are both small-cap asset management industry companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

BioPharma Credit has higher revenue and earnings than River and Mercantile Group. River and Mercantile Group is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£132.06M0.08£10.42B£11.400.08
River and Mercantile Group£74.82M0.00N/A-£2.20N/A

BioPharma Credit has a net margin of 92.62% compared to River and Mercantile Group's net margin of 0.00%. BioPharma Credit's return on equity of 11.29% beat River and Mercantile Group's return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit92.62% 11.29% 4.98%
River and Mercantile Group N/A N/A N/A

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 729.2%. River and Mercantile Group pays an annual dividend of GBX 0.09 per share. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. River and Mercantile Group pays out -4.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, BioPharma Credit's average media sentiment score of 0.00 equaled River and Mercantile Group'saverage media sentiment score.

Company Overall Sentiment
BioPharma Credit Neutral
River and Mercantile Group Neutral

31.3% of BioPharma Credit shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

BioPharma Credit beats River and Mercantile Group on 9 of the 10 factors compared between the two stocks.

How does BioPharma Credit compare to BlackRock Income and Growth?

BlackRock Income and Growth (LON:BRIG) and BioPharma Credit (LON:BPCR) are both small-cap financial services companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

BioPharma Credit has higher revenue and earnings than BlackRock Income and Growth. BioPharma Credit is trading at a lower price-to-earnings ratio than BlackRock Income and Growth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BlackRock Income and Growth£7.07M6.05£6.90M£34.866.60
BioPharma Credit£132.06M0.08£10.42B£11.400.08

0.7% of BlackRock Income and Growth shares are held by institutional investors. Comparatively, 31.3% of BioPharma Credit shares are held by institutional investors. 3.8% of BlackRock Income and Growth shares are held by company insiders. Comparatively, 0.1% of BioPharma Credit shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

BioPharma Credit has a net margin of 92.62% compared to BlackRock Income and Growth's net margin of 88.25%. BlackRock Income and Growth's return on equity of 14.31% beat BioPharma Credit's return on equity.

Company Net Margins Return on Equity Return on Assets
BlackRock Income and Growth88.25% 14.31% 2.59%
BioPharma Credit 92.62%11.29%4.98%

BlackRock Income and Growth pays an annual dividend of GBX 7.70 per share and has a dividend yield of 3.3%. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 729.2%. BlackRock Income and Growth pays out 22.1% of its earnings in the form of a dividend. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, BlackRock Income and Growth's average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score.

Company Overall Sentiment
BlackRock Income and Growth Neutral
BioPharma Credit Neutral

BlackRock Income and Growth has a beta of 0.62268645, suggesting that its share price is 38% less volatile than the broader market. Comparatively, BioPharma Credit has a beta of 0.176, suggesting that its share price is 82% less volatile than the broader market.

Summary

BlackRock Income and Growth beats BioPharma Credit on 7 of the 13 factors compared between the two stocks.

How does BioPharma Credit compare to ScotGems?

ScotGems (LON:SGEM) and BioPharma Credit (LON:BPCR) are both small-cap asset management industry companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

31.3% of BioPharma Credit shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

ScotGems pays an annual dividend of GBX 4 per share. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 729.2%. ScotGems pays out 5,714.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. BioPharma Credit is clearly the better dividend stock, given its higher yield and lower payout ratio.

BioPharma Credit has a net margin of 92.62% compared to ScotGems' net margin of 0.00%. BioPharma Credit's return on equity of 11.29% beat ScotGems' return on equity.

Company Net Margins Return on Equity Return on Assets
ScotGemsN/A N/A N/A
BioPharma Credit 92.62%11.29%4.98%

BioPharma Credit has higher revenue and earnings than ScotGems. ScotGems is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ScotGems£5.07M0.00N/A£0.07N/A
BioPharma Credit£132.06M0.08£10.42B£11.400.08

In the previous week, ScotGems' average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score.

Company Overall Sentiment
ScotGems Neutral
BioPharma Credit Neutral

Summary

BioPharma Credit beats ScotGems on 9 of the 10 factors compared between the two stocks.

How does BioPharma Credit compare to NB Global Monthly Income Fund Ltd GBP?

BioPharma Credit (LON:BPCR) and NB Global Monthly Income Fund Ltd GBP (LON:NBMI) are both small-cap financial services companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 729.2%. NB Global Monthly Income Fund Ltd GBP pays an annual dividend of GBX 9 per share. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. NB Global Monthly Income Fund Ltd GBP pays out 5,294.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit is clearly the better dividend stock, given its higher yield and lower payout ratio.

BioPharma Credit has higher revenue and earnings than NB Global Monthly Income Fund Ltd GBP. NB Global Monthly Income Fund Ltd GBP is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£132.06M0.08£10.42B£11.400.08
NB Global Monthly Income Fund Ltd GBPN/AN/AN/A£0.17N/A

BioPharma Credit has a net margin of 92.62% compared to NB Global Monthly Income Fund Ltd GBP's net margin of 0.00%. BioPharma Credit's return on equity of 11.29% beat NB Global Monthly Income Fund Ltd GBP's return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit92.62% 11.29% 4.98%
NB Global Monthly Income Fund Ltd GBP N/A N/A N/A

In the previous week, BioPharma Credit's average media sentiment score of 0.00 equaled NB Global Monthly Income Fund Ltd GBP'saverage media sentiment score.

Company Overall Sentiment
BioPharma Credit Neutral
NB Global Monthly Income Fund Ltd GBP Neutral

31.3% of BioPharma Credit shares are owned by institutional investors. Comparatively, 44.3% of NB Global Monthly Income Fund Ltd GBP shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by company insiders. Comparatively, 0.2% of NB Global Monthly Income Fund Ltd GBP shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

BioPharma Credit beats NB Global Monthly Income Fund Ltd GBP on 7 of the 10 factors compared between the two stocks.

Get BioPharma Credit News Delivered to You Automatically

Sign up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BPCR vs. The Competition

Export
MetricBioPharma CreditAsset Management IndustryFinancial SectorLON Exchange
Market Cap£10.77M£2.54B£6.21B£2.78B
Dividend Yield7.29%6.00%5.24%6.13%
P/E Ratio0.0862.8430.12368.63
Price / Sales0.081,850.861,180.5484,796.26
Price / Cash1.1960.3388.6827.87
Price / Book0.012.167.157.77
Net Income£10.42B£265.27M£1.13B£5.89B
7 Day PerformanceN/A1.86%0.96%1.32%
1 Month Performance1.48%1.56%0.76%-0.69%
1 Year Performance9.09%8.37%16.00%62.54%

BioPharma Credit Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BPCR
BioPharma Credit
N/AGBX 0.96
flat		N/A+9.1%£10.77M£132.06M0.08N/A
LGT
Lighthouse Group
N/AN/AN/AN/A£42.46M£53.42M18.47156
RIV
River and Mercantile Group
N/AN/AN/AN/A£42.40M£74.82MN/A300
BRIG
BlackRock Income and Growth
N/AGBX 226
-0.4%		N/A+11.7%£42.09M£6.20M7.48N/A
SGEM
ScotGems
N/AN/AN/AN/A£42.02M£5.07M1,121.43N/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:BPCR) was last updated on 7/15/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel